You may never have heard of Alström Syndrome. With an estimated 1 in a million worldwide being affected by this rare genetic disorder, it’s no surprise that it’s not common knowledge. There are only 950 confirmed cases. Despite its rarity, understanding Alström Syndrome’s impact is crucial as it affects multiple organ systems within the body, causing severe health implications.
Alström Syndrome is a rare genetic condition linked to mutations in the ALMS1 gene. This gene's role is to produce the Alström protein, essential for various cellular structures' functions in our bodies. A crucial structure is cilia – hair-like formations that play a significant role in cell signaling and movement. The progression from gene mutation to Alström Syndrome isn't entirely clear, but what is apparent is the harm this condition causes when present.
Symptoms can become apparent as early as infancy and worsen over time. These can differ greatly between individuals, highlighting the importance of an early diagnosis.
Diagnosis can often be challenging, due largely to the condition's rarity and varying symptom manifestations. Clinicians typically combine genetic testing to identify mutations in the ALMS1 gene, alongside specialized evaluations, and imaging studies to determine organ involvement levels. On average, it takes many years for the right diagnosis.
As of now, there is no cure for Alström Syndrome. However, some treatments exist, only focussing on managing symptoms and reducing complications. These usually involve multidisciplinary efforts with the involvement of ophthalmologists, cardiologists, endocrinologists, and geneticists.
Treatments like these might help a little, but it’s not enough. We need to start looking for permanent solutions.
Organizations like Alström Syndrome International (ASI) play a critical role in advancing our knowledge of the disease and offering resources and support to affected individuals and their families. These organizations' efforts significantly contribute to research, raise awareness, and ensure those affected by Alström Syndrome are not alone. But it can’t be that independent organisations have to make almost all the effort in research. We need to drive for change in orphan drug development.
Thank you, we'll be in touch soon.